News | Myriad Genetics

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

Dec 30, 2019 | Pipeline | Products

Myriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors

Dec 19, 2019 | Corporate

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

Dec 14, 2019 | Pipeline | Products

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

Dec 04, 2019 | Pipeline | Products

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

Dec 03, 2019 | Products | Pipeline

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

Nov 21, 2019 | Products

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis

Nov 20, 2019 | Pipeline | Products

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

Nov 11, 2019 | Pipeline | Products

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

Nov 09, 2019 | Pipeline | Products

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference

Nov 07, 2019 | Corporate

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Nov 04, 2019 | Financial

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

Nov 01, 2019 | Products | Pipeline

Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019

Oct 30, 2019 | Corporate

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

Oct 28, 2019 | Products | Pipeline

FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer

Oct 23, 2019 | Products

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience

Oct 21, 2019 | Corporate

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

Oct 08, 2019 | Pipeline | Products

Myriad Genetics Expands Board of Directors with Two Additional Members

Sep 25, 2019 | Corporate

Myriad Announces Research Collaboration with University of Leeds

Sep 16, 2019 | Pipeline | Products

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

Sep 05, 2019 | Pipeline | Products

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference

Aug 30, 2019 | Corporate

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

Aug 22, 2019 | Products | Pipeline

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Aug 13, 2019 | Financial

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Aug 07, 2019 | Pipeline | Products

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

Aug 06, 2019 | Financial | Corporate

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Jun 27, 2019 | Products | Pipeline

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

Jun 25, 2019 | Products

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

Jun 19, 2019 | Products

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

Jun 05, 2019 | Corporate

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

Jun 03, 2019 | Products | Pipeline

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

Jun 02, 2019 | Pipeline | Products

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

May 14, 2019 | Products

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

May 09, 2019 | Pipeline | Products

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

May 07, 2019 | Financial

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

May 01, 2019 | Pipeline | Products

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

May 01, 2019 | Financial | Corporate

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

Apr 30, 2019 | Products

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

Apr 23, 2019 | Financial | Corporate

Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

Apr 23, 2019 | Products

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

Apr 17, 2019 | Corporate

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

Apr 09, 2019 | Pipeline | Products

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

Apr 04, 2019 | Pipeline | Products

Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

Apr 02, 2019 | Products | Pipeline

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

Mar 21, 2019 | Pipeline | Products

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

Mar 14, 2019 | Products | Pipeline

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine

Mar 06, 2019 | Products | Pipeline

Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib

Feb 26, 2019 | Pipeline | Products

Vectra® Study Published in the Journal Current Medical Research & Opinion

Feb 22, 2019 | Pipeline | Products

Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer

Feb 15, 2019 | Products

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

Feb 13, 2019 | Corporate

Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs

Feb 11, 2019 | Pipeline | Products

Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting

Feb 08, 2019 | Pipeline | Products

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Feb 05, 2019 | Financial

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019

Jan 28, 2019 | Corporate

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

Myriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

Myriad Genetics Expands Board of Directors with Two Additional Members

Myriad Announces Research Collaboration with University of Leeds

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine

Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib

Vectra® Study Published in the Journal Current Medical Research & Opinion

Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

Myriad Announces Prequel™ Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs

Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019